Q1 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Neurogene in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings per share of ($1.12) for the quarter. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($4.76) EPS and FY2026 earnings at ($6.03) EPS.

Other equities research analysts also recently issued reports about the stock. HC Wainwright lowered their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday. William Blair reissued an “outperform” rating on shares of Neurogene in a report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $59.80.

Neurogene Stock Down 5.0 %

NASDAQ:NGNE opened at $15.33 on Thursday. The stock has a market cap of $227.73 million, a P/E ratio of -3.59 and a beta of 1.01. The business’s 50-day moving average price is $16.92 and its two-hundred day moving average price is $28.96. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter.

Institutional Trading of Neurogene

Institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. purchased a new position in shares of Neurogene in the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. purchased a new stake in Neurogene during the 4th quarter valued at about $72,000. Virtus ETF Advisers LLC grew its position in Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after acquiring an additional 989 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Neurogene by 34.5% in the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock valued at $124,000 after purchasing an additional 1,397 shares during the last quarter. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 9.92% of the stock is currently owned by corporate insiders.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.